NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Significant Increase in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 3,527,843 shares, a growth of 92.7% from the December 31st total of 1,831,090 shares. Based on an average daily volume of 2,710,433 shares, the days-to-cover ratio is currently 1.3 days. Approximately 14.7% of the shares of the company are short sold. Approximately 14.7% of the shares of the company are short sold. Based on an average daily volume of 2,710,433 shares, the days-to-cover ratio is currently 1.3 days.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, January 21st. BTIG Research restated a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, January 15th. Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research note on Monday, December 29th. Ascendiant Capital Markets reiterated a “buy” rating and issued a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. Finally, D. Boral Capital reissued a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a report on Monday, January 5th. Four investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $36.75.

NRx Pharmaceuticals Trading Down 0.9%

Shares of NRx Pharmaceuticals stock traded down $0.02 during trading on Friday, hitting $2.10. The stock had a trading volume of 379,991 shares, compared to its average volume of 1,785,069. The business has a fifty day moving average of $2.31 and a two-hundred day moving average of $2.66. NRx Pharmaceuticals has a fifty-two week low of $1.58 and a fifty-two week high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $6.83 million. On average, equities analysts forecast that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Sjbenen Advisory LLC purchased a new position in shares of NRx Pharmaceuticals during the fourth quarter valued at $41,000. One Wealth Management Investment & Advisory Services LLC lifted its position in shares of NRx Pharmaceuticals by 35.3% in the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock worth $103,000 after purchasing an additional 9,882 shares in the last quarter. Anson Funds Management LP boosted its holdings in shares of NRx Pharmaceuticals by 26.2% during the third quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock worth $6,683,000 after purchasing an additional 420,129 shares during the period. Two Sigma Investments LP grew its position in NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in NRx Pharmaceuticals by 18.3% during the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares in the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.